Peptide YY levels are decreased by fasting and elevated following caloric intake but are not regulated by leptin

被引:49
作者
Chan, JL [1 ]
Stoyneva, V [1 ]
Kelesidis, T [1 ]
Raciti, P [1 ]
Mantzoros, CS [1 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Sch Med,Dept Med, Boston, MA 02215 USA
关键词
appetite; fasting; leptin; obesity; peptide YY;
D O I
10.1007/s00125-005-0041-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis: Peptide YY (PYY) is a gut-derived hormone that has been shown to reduce short-term food intake in animals and humans. It has been proposed that deficiency of PYY contributes to obesity in humans. However, the physiology of PYY regulation by factors such as caloric restriction, or by other molecules important in energy homeostasis, e.g. leptin, remains to be fully elucidated. Materials and methods: We evaluated the effect on PYY levels of: (1) caloric ingestion (a mixed meal) in five healthy normal-weight subjects; (2) fasting for 2 or 3 days in eight lean men and seven lean women respectively; and (3) recombinant human leptin administration at physiological replacement and pharmacological doses. Results: PYY levels increased 50% after a mixed meal (p=0.01), and short-term complete fasting for 2 or 3 days decreased leptin and PYY levels to 20-30% and 40-60% of baseline, respectively (both p < 0.05). However, recombinant human leptin administration at physiological doses to restore the fasting-induced decrease of leptin levels and at pharmacological doses over the short term had no effect on PYY levels. Conclusions/interpretation: PYY increases after meal ingestion and decreases after fasting in a manner consistent with a meal-related signal of energy homeostasis. Importantly, circulating levels of this gut-secreted molecule are independent of regulation by leptin over the short term. These findings contribute towards our understanding of the homeostatic systems that regulate appetite in humans, including the possible redundancy of gastrointestinally secreted and adipocyte-secreted signals. This may be of importance for the future development of medications to treat obesity.
引用
收藏
页码:169 / 173
页数:5
相关论文
共 16 条
[1]   HUMAN DISTRIBUTION AND RELEASE OF A PUTATIVE NEW GUT HORMONE, PEPTIDE-YY [J].
ADRIAN, TE ;
FERRI, GL ;
BACARESEHAMILTON, AJ ;
FUESSL, HS ;
POLAK, JM ;
BLOOM, SR .
GASTROENTEROLOGY, 1985, 89 (05) :1070-1077
[2]   Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty [J].
Bartolomé, MA ;
Borque, M ;
Martinez-Sarmiento, J ;
Aparicio, E ;
Hernández, C ;
Cabrerizo, L ;
Fernández-Represa, JA .
OBESITY SURGERY, 2002, 12 (03) :324-327
[3]   Gut hormone PYY3-36 physiologically inhibits food intake [J].
Batterham, RL ;
Cowley, MA ;
Small, CJ ;
Herzog, H ;
Cohen, MA ;
Dakin, CL ;
Wren, AM ;
Brynes, AE ;
Low, MJ ;
Ghatei, MA ;
Cone, RD ;
Bloom, SR .
NATURE, 2002, 418 (6898) :650-654
[4]   Inhibition of food intake in obese subjects by peptide YY3-36 [J].
Batterham, RL ;
Cohen, MA ;
Ellis, SM ;
Le Roux, CW ;
Withers, DJ ;
Frost, GS ;
Ghatei, MA ;
Bloom, SR .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (10) :941-948
[5]   Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse [J].
Challis, BG ;
Pinnock, SB ;
Coll, AP ;
Carter, RN ;
Dickson, SL ;
O'Rahilly, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 311 (04) :915-919
[6]   Ghrelin levels are not regulated by recombinant leptin administration and/or three days of fasting in healthy subjects [J].
Chan, JL ;
Bullen, J ;
Lee, JH ;
Yiannakouris, N ;
Mantzoros, CS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (01) :335-343
[7]   Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-α receptor levels in humans with relative leptin deficiency [J].
Chan, JL ;
Moschos, SJ ;
Bullen, J ;
Heist, K ;
Li, X ;
Kim, YB ;
Kahn, BB ;
Mantzoros, CS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1625-1631
[8]  
Chan JL, 2003, J CLIN INVEST, V111, P1409, DOI 10.1172/JCI200317490
[9]   Serum immunoreactive leptin concentrations in normal-weight and obese humans [J].
Considine, RV ;
Sinha, MK ;
Heiman, ML ;
Kriauciunas, A ;
Stephens, TW ;
Nyce, MR ;
Ohannesian, JP ;
Marco, CC ;
McKee, LJ ;
Bauer, TL ;
Caro, JF .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :292-295
[10]   Recombinant leptin for weight loss in obese and lean adults - A randomized, controlled, dose-escalation trial [J].
Heymsfield, SB ;
Greenberg, AS ;
Fujioka, K ;
Dixon, RM ;
Kushner, R ;
Hunt, T ;
Lubina, JA ;
Patane, J ;
Self, B ;
Hunt, P ;
McCamish, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (16) :1568-1575